Fig. 2: NR treatment improves the lymphoid potential of HSCs from aged mice.
From: NAD+ augmentation with nicotinamide riboside improves lymphoid potential of Atm−/− and old mice HSCs
a, b Frequency analysis of early progenitor compartments in NR-treated (NR) or untreated bone marrow from young (Y-WT, 3–4 months) or aged (O-WT, 24–29 months) mice (n = 4–10). c Peripheral blood chimerism generated from 200 purified HSCs against 2 × 105 competitor cells every 4 weeks for 4 months (n = 10). d Lineage composition of donor derived peripheral blood 4 months post transplant (n = 10). Data are represented as mean ± SEM. Kruskal–Wallis test for a and b, two-way ANOVA for c and d: <0.05*, <0.01**, <0.001***.
